Replies to post #317742 on Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

Interesting observations.

The concentration issue in general has always confused me. My layman understanding of the term, which may be inappropriate, is simply the amount of one substance relative to another. Easy example: 1ml B with 9ml DMSO*** would be a 10% concentration.

What I don't understand is why it matters when comparing one drug to another....I'm sure there's a simple explanation but I don't know what it is.
If a 10% concentration of Drug A is as effective and safe as a 20% concentration of Drug B what are the issues that make one preferable to the other?
(there are definitely a few people here that can answer that)
That said, you're right about the use of....."at a concentration similar to"....when the specifics had to have been available.


"Was Remdesivir not tested in lung epithelial cell lines?"
Good question. I didn't look into the details of the results and probably wouldn't have understood them if I did, but the answer to your question is pretty clear:

"Date:
July 9, 2020
Source:
Vanderbilt University Medical Center
Summary:
A new study found that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus. "
https://www.sciencedaily.com/releases/2020/07/200709172845.htm

It's obviously not as simple as "90% is better than 50%", even if some are satisfied with that.



***http://www.ipharminc.com/press-release/2020/7/20/innovation-pharmaceuticals-brilacidin-inhibits-novel-coronavirus-covid-19-by-almost-90-at-the-lowest-concentration-tested-to-date-in-a-human-lung-cell-line

[MinnieM]

It could be an attempt not to use the same verbiage expected to be included in published articles. The US RBL's are unlikely to want to see Leo quoting exactly what they give him. Most publications want info to be new and previously unseen elsewhere.

Just another thought that I see as more likely.





Message in reply to:

I can tell you the issues I have with these specific sentences.

Quote:
"In the RBL assay (which included Brilacidin pre-incubated with virus), Brilacidin exhibited approximately 90 percent inhibition against SARS-CoV-2 at a concentration similar to that of Remdesivir™, which again reported 50 percent inhibition of the coronavirus. The Brilacidin inhibition assay was tested in a human lung epithelial cell line, with Remdesivir™ tested in Vero cells."


Why use the phrase “at a concentration similar to” rather than providing the actual concentration? It implies that there’s something underneath that is not favorable to the writer of the PR.

Why compare results from tests on 2 different cell lines? Was Remdesivir not tested in lung epithelial cell lines? Again, it implies that the lung cell comparison is less favorable to the writer of the PR.

That's what I see.